The safety profile in this study was comparable to that in the phase II trials. Results from a recent paper support the role of oral ABR in patients with moderate or severe eczema in the management of arthritis.
Abrocitinib 200 mg is effective and suitable for use in patients with CLE, not only for those patients with CLE who do not respond well to methotrexate monotherapy. (Int Clin Dermol Ther; 2012;9(11):630-633).
There is no evidence that eczema, infantile can be cured, and even a few cases may increase after stopping treatment for 2 to 4 years.
Eczema, infantile, is an inflammation of the skin affecting approximately 1% of the UK population. Most commonly seen in infants and toddlers, infants with eczema complain of irritation or irritation and inflammation of the skin. Children with eczema often have itched, red or swollen patches on their skin. The condition can be difficult to distinguish from other skin problems such as contact dermatitis, seborrhoea, asthma, contact dermatitis or psoriasis. The exact cause of eczema, infantile is not yet understood. There is no cure and the best way to treat infants, eczema, infantile is to manage it.
A history of atopy and a skin-prick test are suggestive of eczema, infantile, but histology may be necessary in the later stages. The features of infantile eczema are similar to other primary care dermatological problems.
Eczema is commonly treated through a variety of styles of therapy, including dermatologists, primary care physicians, and parents. Antihistamines are commonly used. Eczema is not a disease where one patient is uniformly responding to treatment, so other medical and psychosocial considerations are needed before turning to treatment.
Data from a recent study reveals a relatively high prevalence of eczema in the US population. The data suggest that more than 1 in 5 children at 5 months of age have eczema.
The presence of eczema is strongly associated with allergic predisposition as determined by a positive skin-prick test, positive immunological markers, and a favorable response to allergen therapy. The most common eczema subtype in children was atopic dermatitis.
Eczema, infantile can be a serious illness, at least in older children, depending on all of the individual factors. At the same time, the outcome can be good, as in some cases eczema, infantile could disappear without recurring, even in later life. The presence of a parent has some effect upon the outcome: the best outcome is always found in cases with at least one child who does not have eczema or any other allergic diseases.
The clinical trial design used to evaluate abrocitinib 200 mg in 3 different indications showed comparable safety and tolerability profile versus placebo in three indications. A randomized study versus placebo was planned in psoriasis, but was discontinued when a meta-analysis indicated possible increased risks in patients randomized to an abrocitinib-treated group, which are likely to be outweighed by the benefits for patients using this treatment.
The average age of diagnosis of eczema, infantile has been increased over the past decade. This is likely an effect of a reduction in the number of cases and the fact that individuals have had longer life spans. There are many possible factors which may contribute to the increase.